α-Melanocyte-stimulating hormone alleviates pathological cardiac remodeling via melanocortin 5 receptor.
This study indicates that α-MSH may protect against cardiac remodeling in mice, but further research is necessary to determine its relevance in humans.
Where it sits
this study against the rest of the melanotan i (mt-i) corpusSummary and findings
This study investigates the role of α-Melanocyte-stimulating hormone (α-MSH) in pathological cardiac remodeling using a mouse model. The administration of a stable α-MSH analog was found to protect against transverse aortic constriction (TAC)-induced cardiac hypertrophy and systolic dysfunction. The study highlights the involvement of melanocortin 5 receptor (MC5-R) in mediating these effects.
Abstract
α-Melanocyte-stimulating hormone (α-MSH) regulates diverse physiological functions by activating melanocortin receptors (MC-R). However, the role of α-MSH and its possible target receptors in the heart remain completely unknown. Here we investigate whether α-MSH could be involved in pathological cardiac remodeling. We found that α-MSH was highly expressed in the mouse heart with reduced ventricular levels after transverse aortic constriction (TAC). Administration of a stable α-MSH analog protected mice against TAC-induced cardiac hypertrophy and systolic dysfunction. In vitro experiments revealed that MC5-R in cardiomyocytes mediates the anti-hypertrophic signaling of α-MSH. Silencing of MC5-R in cardiomyocytes induced hypertrophy and fibrosis markers in vitro and aggravated TAC-induced cardiac hypertrophy and fibrosis in vivo. Conversely, pharmacological activation of MC5-R improved systolic function and reduced cardiac fibrosis in TAC-operated mice. In conclusion, α-MSH is expressed in the heart and protects against pathological cardiac remodeling by activating MC5-R in cardiomyocytes. These results suggest that analogs of naturally occurring α-MSH, that have been recently approved for clinical use and have agonistic activity at MC5-R, may be of benefit in treating heart failure.
Background
The paper addresses the role of α-Melanocyte-stimulating hormone (α-MSH) in cardiac remodeling, a process associated with various cardiovascular diseases. Prior research has indicated that melanocortin receptors, particularly the melanocortin 5 receptor, may influence cardiac function. This study is significant as it explores a potential therapeutic target for mitigating cardiac remodeling.
Methods
The study utilized a rodent model to investigate the effects of α-MSH on cardiac remodeling. Specific details regarding the number of subjects (n), dosing regimen, duration of treatment, and outcome measures were not reported in the abstract.
Results
Not reported in abstract.
Interpretation
Without specific numeric findings, it is challenging to compare this study's results to existing literature or to evaluate the clinical significance of the observed effects. The absence of detailed outcomes raises concerns about the robustness of the conclusions drawn. The reliance on a rodent model also limits the applicability of the findings to human populations.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Rodent model limits human applicability.
- Specific numeric outcomes not provided.